Compare Summit Therapeutics Inc (SMMT) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.79. Which is the better fit depends on your goals.
| SMMT | XLY | |
|---|---|---|
Market Cap | $13.79B | — |
Sector | Health | — |
52-Week High | $26.38 | $124.52 |
52-Week Low | $12.43 | $105.64 |
Enterprise Value | $13.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
XLY trades at $113.99, down 0.8% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF maintains 100% analyst buy ratings, reflecting confidence in consumer discretionary exposure despite current market weakness. Recent news highlights XLY as a potential sleeper opportunity for Q3 2026, with consumer spending trends supporting the sector's long-term prospects.
The outlook remains constructive given unanimous analyst support and consumer resilience, though technical weakness and sector concentration risks require monitoring. Upside potential exists if consumer discretionary spending accelerates, while economic slowdowns could pressure performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
